Autoimmune liver disease

Current Opinion in Gastroenterology

Volumn 19, Issue 3, 2003, Pages 232-242

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BUDESONIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEFLAZACORT; EVEROLIMUS; HLA DR ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LIVER ANTIGEN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 10; TACROLIMUS; THALIDOMIDE; URSODEOXYCHOLIC ACID;

ALLELE; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; CELL ULTRASTRUCTURE; CHILD; CHOLANGITIS; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; ETHNIC GROUP; FEMALE; GLUTEN FREE DIET; GRAFT FAILURE; HISTOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER NECROSIS; LIVER TRANSPLANTATION; MALE; MOLECULAR MIMICRY; PATHOGENESIS; REVIEW; RISK FACTOR; SYMPTOM;

EID: 0037404178     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200305000-00006     Document Type: Review

References (66)

1. McFarlane IG: Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis 2002, 6:605-621.
2. McFarlane IG: Definition and classification of autoimmune hepatitis. Semin Liver Dis 2002, 22:317-324.
3. Czaja AJ, Freese DK: Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002, 36:479-497. Provides evidence-based practice guidelines sponsored by the American Association for the Study of Liver Diseases, which are intended to be flexible aids for the use of clinicians caring for autoimmune hepatitis.
4. Kim WR, Brown RS Jr, Terrault NA, et al.: Burden of liver disease in the United States: summary of a workshop. Hepatology 2002, 36:227-242.
5. Boberg KM: Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002, 6:635-647.
6. Talwalkar JA, Kim WR: Medical and economic impact of autoimmune hepatitis. Clin Liver Dis 2002, 6:649-667.
7. Lim KN, Casanova RL, Boyer TD, et al.: Autoimmune hepatitis in African Americans: presenting features and responses to therapy. Am J Gastroenterol 2001, 96:3390-3394.
8. Hurlburt KJ, McMahon BJ, Deubner H, et al.: Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol 2002, 97:2402-2407.
9. Kosar Y, Kacar S, Sasmaz N, et al.: Type 1 autoimmune hepatitis in Turkish patients: absence of association with HLA B8. J Clin Gastroenterol 2002, 35:185-190.
10. Zolfino T, Heneghan MA, Norris S, et al.: Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut 2002, 50:713-717.
11. Saadah OI, Smith AL, Hardikar W: Long-term outcome of autoimmune hepatitis in children. J Gastroenterol Hepatol 2001, 16:1297-1302. A comprehensive, retrospective review of clinical experience with childhood autoimmune hepatitis that spans 28 years and provides another perspective of the disease outside northern Europe.
12. Mieli-Vergani G, Vergani D: Autoimmune hepatitis in children. Clin Liver Dis 2002, 6:623-634. This well-characterized, large patient cohort provides unique insights into the autoimmune hepatitis of children, its variant form of autoimmune sclerosing cholangitis, and de novo autoimmune hepatitis after liver transplantation.
13. Redondo-Cerezo E, Nogueras-Lopez F, Martin-Vivaldi R, et al.: Fulminant hepatic failure as the presenting form of type 1 autoimmune hepatitis in the elderly. Am J Gastroenterol 2002, 97:1265-1266.
14. van Leeuwen DJ, Sood G, Ferrante D, et al.: A 38-year-old African-American woman with an unusually rapid progression of "primary biliary cirrhosis": a missed opportunity! Semin Liver Dis 2002, 22:395-405.
15. Hartleb M, Nowak A, Kajor M, et al: Autoimmune LKM1 hepatitis presenting in the form of recurrent acute episodes. Am J Gastroenterol 2002, 97:1267-1268.
16. Kogan J, Safadi R, Ashur Y, et al.: Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J Clin Gastroenterol 2002, 35:75-81.
17. Rumbo C, Betzhold J, Merati S, et al.: Autoimmune hyperlipidemia in a child with autoimmune hepatitis. J Clin Gastroenterol 2002, 35:196-199.
18. Kaukinen K, Halme L, Collin P, et al.: Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology 2002, 122:881-888.
19. Volta U, Rodrigo L, Granito A, et al.: Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002, 97:2609-2613.
20. Sedlack RE, Smyrk TC, Czaja AJ, et al.: Celiac disease-associated autoimmune cholangitis. Am Clin Gastroenterol 2002, 97:3196-3198.
21. Carpenter HA, Czaja AJ: The role of histologic evaluation in the diagnosis and treatment of autoimmune hepatitis and its variants. Clin Liver Dis 2002, 6:685-705. A comprehensive review of the indications and expectations of liver tissue examination in autoimmune hepatitis and its variant syndromes.
22. Singh R, Nair S, Farr G, et al.: Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol 2002, 97:2670-2673.
23. Sata Y, Harada K, Sudo Y, et al.: Autoimmune hepatitis associated with bile duct injury resembling chronic non-suppurative destructive cholangitis. Pathol Int 2002, 52:478-482.
24. Dalekos GN, Zachou K, Liaskos C, et al.: Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002, 13:293-303.
25. Bianchi FB, Muratori P, Muratori L: New autoantibodies and autoantigens in autoimmune hepatitis. Clin Liver Dis 2002, 6:785-797.
26. Strassburg CP, Manns MP: Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis 2002, 22:339-351.
27. Muratori P, Muratori L, Cassani F, et al.: Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibodies in hepatic and rheumatological disorders. Clin Exp Immunol 2002, 127:172-175.
28. Baeres M, Herkel J, Czaja AJ, et al.: Establishment of standarised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002, 51:259-264.
29. Czaja AJ, Donaldson PT, Lohse AW: Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002, 97:413-419. Important observations indicating that the expression of anti-SLA/LP is associated with the principal genetic risk factor for autoimmune hepatitis and invariably associated with relapse after corticosteroid withdrawal. Antibodies to SLA/LP may be surrogate markers of a genetic propensity to relapse and may have prognostic value.
30. (Ser)Sec antigen that conserves conformational epitopes, demonstrates high seropositivity in autoimmune hepatitis, and associates with disease severity and prognosis.
31. Herkel J, Heidrich B, Nieraad N, et al.: Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. Hepatology 2002, 35:403-408. An excellent application of a scientific method to define the dominant epitope of anti-SLA/LP and to explore molecular mimicries with viral antigens that might generate the antibody response.
32. Skoog SM, Rivard RE, Batts KP, et al.: Autoimmune hepatitis preceded by acute hepatitis A infection. Am J Gastroenterol 2002, 97:1568-1569.
33. Nishiguchi S, Enomoto M, Shiomi S, et al.: GB virus C and TTV virus infections in Japanese patients with autoimmune hepatitis. J Med Virol 2002, 66:258-262.
34. Czaja AJ, Doherty DG, Donaldson PT: Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002, 47:2139-2150. A scholarly, in-depth review of the molecular mechanisms of antigen presentation and immunocyte activation in autoimmune hepatitis as affected by gender, alleles that encode the antigen binding groove of the HLA DR molecule, and alleles that promote autoimmunity in a non-disease-specific fashion.
35. Donaldson PT, Czaja AJ: Genetic effects on susceptibility, clinical expression, and outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002, 6:707-725. An important review of the hypotheses generated by the available data to explain the genetic factors influencing the occurrence, clinical features, and treatment response of autoimmune hepatitis.
36. Donaldson PT: Genetics in autoimmune hepatitis. Semin Liver Dis 2002, 22:353-363. An erudite discussion of the strengths and weaknesses of the current theories of pathogenesis of autoimmune hepatitis, including the hypotheses of shared motif, autoimmune promoter, and molecular footprint.
37. Djilali-Saiah I, Ouellette P, Caillat-Zucman S, et al.: CTLA-4/CD28 region polymorphisms in children from families with autoimmune hepatitis. Hum Immunol 2001, 62;1356-1362. An important confirmatory study demonstrating that autoimmune promoter genes outside the MHC can affect disease occurrence and indicating that type 1 and type 2 autoimmune hepatitis have different genetic predispositions.
38. Czaja AJ, Souto EO, Bittencourt PL, et al.: Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002, 37:302-308. An important study verifying the similarity of autoimmune hepatitis in Brazil and the United States and its association with DRB1 *1301 in South America, especially among children. Similar frequencies of HLA DR13 and HLA DR3 in control subjects from each country suggest that a region-specific, indigenous agent selects genetically susceptible patients from the normal pool.
39. Vogel A, Strassburg CP, Manns MP: Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002, 35:126-131.
40. Czaja AJ, Donaldson PT: Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002, 97:2051-2057. An interesting analysis that provides some insight into mechanisms by which women may be at greater risk for autoimmune hepatitis than men. By having a higher frequency of non-DRB1 *0401 DR4 alleles than men, women may react to a greater diversity of autoantigens.
41. Dienes HP, Erberich H, Dries V, et al.: Autoimmune hepatitis and overlap syndromes. Clin Liver Dis 2002, 6:349-362.
42. Heathcote J: Variant syndromes of autoimmune hepatitis. Clin Liver Dis 2002, 6:669-684.
43. Talwalkar JA, Keach JC, Angulo P, et al.: Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002, 97:1191-1197.
44. Joshi S, Cauch-Dudek K, Wanless IR, et al.: Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002, 35:409-413.
45. Rose NR: Mechanisms of autoimmunity. Semin Liver Dis 2002, 22:387-394.
46. Vergani D, Choudhuri K, Bogdanos DP, et al.: Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002, 6:727-737. A cogent explanation of the putative pathogenic mechanisms of autoimmune hepatitis, invoking molecular mimicry as the most likely, but still unproved consideration.
47. Vogel A, Manns MP, Strassburg CP: Autoimmunity and viruses. Clin Liver Dis 2002, 6:739-753. A lucid discourse on the possible mechanisms of virus-induced autoimmunity, including concepts of molecular mimicry, bystander activation, and superantigen stimulation.
48. Liu Z-X, Kaplowitz N: Immune-mediated drug-induced liver disease. Clin Liver Dis 2002, 6:755-774. A valuable exposition of putative immune mechanisms of drug-induced liver injury, emphasizing the hapten and danger hypotheses. A useful clinical guide in diagnosing suspected drug-related liver disease.
49. Jaeckel E: Animal models of autoimmune hepatitis. Semin Liver Dis 2002, 22:325-337.
50. Howell CD: Animal models of autoimmunity. Clin Liver Dis 2002, 6:775-783.
51. Al-Khalidi JA, Czaja AJ: Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. Mayo Clin Proc 2001, 76:1237-1252. A comprehensive update of the international criteria for the diagnosis of autoimmune hepatitis and a practical review of the genetic predispositions, pathogenic pathways, and management strategies for the disease.
52. Czaja AJ: Emerging treatments of autoimmune hepatitis. Current Drug Targets-Inflammation & Allergy 2002, 1:317-326.
53. Czaja AJ: Treatment of autoimmune hepatitis. Semin Liver Dis 2002, 22:365-377. Presents conventional and empiric treatment strategies for treatment-naïve and problematic patients with autoimmune hepatitis. Mechanisms of drug action and sites of possible therapeutic intervention are provided.
54. Czaja AJ: Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002, 6:799-824. Presents important practical algorithms for managing a spectrum of problems.
55. Vierling JM, Flores PA: Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002, 6:825-850. A comprehensive review of emerging and feasible treatment options that have had limited or no clinical trial.
56. Venkataramani A, Jones MB, Sorrell MF: Methotrexate therapy for refractory chronic active autoimmune hepatitis. Am J Gastroenterol 2001, 96:3432-3434.
57. Czaja AJ, Menon KVN, Carpenter HA: Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002, 35:890-897. Analysis of the frequency of sustained remission after corticosteroid withdrawal and justification for pursuing an endpoint of treatment, even after previous relapse and re-treatment.
58. Neuberger J: Transplantation for autoimmune hepatitis. Semin Liver Dis 2002, 22:379-385.
59. Cattan P, Berney T, Conti F, et al.: Outcome of orthotopic liver transplantation in autoimmune hepatitis according to subtypes. Transpl Int 2002, 15:34-38.
60. Faust TW: Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Liver Transpl 2001, 7:S99-S108.
61. Molmenti EP, Netto GJ, Murray NG, et al: Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002, 8:519-526.
62. Petz W, Sonzogni A, Bertani A, et al.: A cause of late graft dysfunction after pediatric liver transplantation: de novo autoimmune hepatitis. Transpl Proc 2002, 34:1958-1959.
63. Salcedo M, Vaquero J, Banares R, et al.: Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002, 35:349-356.
64. Czaja AJ: Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance. Liver Transpl 2002, 8:505-513. Reviews the hypotheses for recurrent and de novo autoimmune hepatitis after liver transplantation, with emphasis on the difficulty in establishing a truly autoimmune basis for allograft dysfunction.
65. Vergani D, Mieli-Vergani G: Autoimmunity after liver transplantation. Hepatology 2002, 36:271-276.
66. Jain A, Pokharna R, Eghtesad B, et al.: Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival. Transpl Proc 2002, 34:1524-1525.